Pages

▼
Tuesday, December 23, 2014

RXi Pharmaceuticals Reality Check

›
Last week on December 17, RXi Pharmaceuticals announced  (3-month) results from a phase II study of the company’s lead candidate RXI-109...
7 comments:
Tuesday, December 16, 2014

Dicerna Behind Alnylam in GalNAc, But Early Data Suggest Clinical Relevance

›
As promised, RNAi Therapeutics fast-follower Dicerna for the first time disclosed last night data on GalNAc-conjugated Dicer-substrate te...
13 comments:
Monday, December 15, 2014

Dicerna About to Disclose Status of GalNAc-Conjugated Dicer Substrates

›
Dicerna is about to hold its annual R&D day tonight and, for the first time, reveal the status of their version of GalNAc-RNAi trigger...
5 comments:
Sunday, December 14, 2014

ISIS and Alnylam Starting to Walk the Talk

›
Talk is one thing, acting on it another.   This has also been true for RNA Therapeutics industry bellwethers ISIS Pharmaceuticals and Al...
4 comments:
Wednesday, December 10, 2014

Alnylam’s Second-Generation GalNAc Data Impress

›
Earlier this week at the American Society of Hematology meeting in San Francisco, Alnylam presented first multi-dose knockdown data in hu...
2 comments:
Monday, December 8, 2014

Factor XI Data by ISIS Pharmaceuticals Revolutionizes Anti-Clotting Field

›
Yesterday, ISIS Pharmaceuticals disclosed in-depth data from their phase II anti-clotting study in about 300 patients undergoing total ...
7 comments:
Wednesday, December 3, 2014

Alnylam Second-Generation GalNAc Chemistry ~5x More Potent

›
The GalNAc-RNAi trigger strategy pioneered by Alnylam and Arrowhead Research has opened up new opportunities for RNAi Therapeutics, part...
7 comments: